The gap between how large pharmaceutical companies and emerging biotechs bring products to market has widened into two fundamentally distinct strategic playbooks.
Jon Hamrick, a partner at Curatio Advisors, argues that the divergence is not simply a matter of resources but reflects deeper structural differences in how each type of organisation operates.
Product attributes play a central role in determining which commercialization approach a company should pursue, according to Hamrick’s analysis of launch strategy.
A therapy targeting a rare disease, for instance, demands a very different go-to-market model than a blockbuster primary-care drug aimed at millions of patients.
Company size shapes not only budget and headcount but also the speed and flexibility with which a team can respond to early commercial signals in the market.
Large pharmaceutical companies typically bring established infrastructure, broad payer relationships, and significant field-force capacity that smaller rivals simply cannot replicate at launch.
Emerging biotechs, by contrast, often compensate with sharper focus, leaner decision-making structures, and a willingness to pursue unconventional routes to reach prescribers and patients.
Stakeholder alignment emerges as another decisive factor, with internal agreement across medical, market access, and commercial functions proving critical to a successful product launch.
Hamrick’s perspective, shared through Curatio Advisors, underscores that misalignment between these functions is among the most common and costly mistakes companies make during the launch window.
The conversation reflects a broader industry reckoning with how commercialization must evolve as the pipeline shifts increasingly toward speciality and rare-disease assets that resist traditional mass-market tactics.
Payer complexity has also intensified, with formulary decisions and prior authorisation requirements forcing both large and small companies to invest earlier and more heavily in market-access strategy.
For biotechs entering their first or second commercial launch, the stakes are particularly high, as a stumble in execution can affect not only revenue but investor confidence and partnership prospects.
The two-playbook framework Hamrick describes suggests there is no universal template, and that companies borrowing indiscriminately from one another’s models risk misreading their own commercial environment.